About the Authors

Jane E. Salmon
Autoimmunity and Inflammation Program, Hospital for Special Surgery, Cornell Weill Medical College, New York, New York, United States of America

Cara Heuser, D. Ware Branch
Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah, United States of America

Michael Triebwasser, M. Kathryn Liszewski, John P. Atkinson
Department of Medicine/Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri, United States of America

David Kavanagh, Tim Goodship
Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, United Kingdom

Lubka Roumenina, Veronique Fremeaux-Bacchi
Assistance Publique-Hopitaux de Paris, Hôpital Européen Georges-Pompidou, Service d'Immunologie Biologique, Paris, France

Corresponding Author


Competing Interests

JES holds stock in Taligen Therapeutics. JPA is on the Scientific Advisory Board and holds stock in Taligen Therapeutics. TG has acted as a Scientific Advisor for Taligen Therapeutics. All other authors have no conflict of interest.

Author Contributions

Conceived and designed the experiments: JES JAP MT VFB TG. Performed the experiments: VFB LR DK MKL TG. Analyzed the data: JES JAP TG MT VFB. Contributed reagents/materials/analysis tools: CH DWB DK MT MKL VBF TG JAP JES. Wrote the paper: JES MT MKL DK VFB JPA. ICMJE criteria for authorship: JES CH MT MKL DK LR DWB TG VFB JPA. Agree with result and conclusions: JES CH MT MKL DK LR DWB VFB TG JPA. Enrolled patients: CH JES DWB TG VFB. Wrote the first draft: JES CH MT MKL DK VFB JPA.